Alkem Laboratories Declares ₹10 Final Dividend, Reports Q4 FY26 Profit Decline

Alkem Laboratories' profit for the quarter ended March 31, 2026, fell 22% to ₹251.11 crore from ₹322.39 crore in the same period last year. The company's revenue from operations, however, saw a healthy increase of 14.7% to ₹3,603.32 crore in Q4 FY26, up from ₹3,143.75 crore in Q4 FY25. For the full fiscal year FY26, revenue grew to ₹14,712.27 crore from ₹12,964.52 crore in FY25. Net profit for FY26 rose to ₹2,351.16 crore from ₹2,215.38 crore.

Reader Takeaway: Revenue growth shows operational strength, while exceptional items and tax changes impact bottom line. Dividend payout remains a positive for shareholders.

What just happened

Alkem Laboratories announced its audited financial results for the fourth quarter and full year ended March 31, 2026. The company's Q4 FY26 net profit declined by 22% to ₹251.11 crore. This decline was influenced by several exceptional items, including a ₹74.70 crore provision for real estate impairment and ₹113.06 crore impact from finalization of Central Rules under the Labour Codes. The company also reported a ₹14.29 crore gain from the sale of its Indore manufacturing facility. Despite the profit dip, revenue from operations rose 14.7% to ₹3,603.32 crore for the quarter.

Why this matters

The results show a mixed picture for investors. While the company's top line (revenue) demonstrates strong growth, signaling robust business operations, the bottom line (profit) was significantly affected by one-time charges. The declaration of a final dividend of ₹10 per equity share, in addition to an interim dividend of ₹43, highlights the company's commitment to returning value to shareholders. The strategic decision to opt for the new tax regime under Section 115BAA from FY27 is a forward-looking move aimed at optimizing tax liabilities.

The backstory

Alkem Laboratories is a leading player in the Indian pharmaceutical industry. The company has consistently focused on expanding its product portfolio and market reach. The recent financial year saw various regulatory developments, including the finalization of Labour Codes, which have led to adjustments in provisions for employee liabilities across the sector. The company's engagement with real estate investments and manufacturing facility sales also represent strategic business decisions.

What changes now

With the Board's recommendation for a ₹10 final dividend, shareholders can anticipate a payout, subject to approval. The record date for this dividend is August 7, 2026. The re-appointment of Mrs. Madhurima Singh as Executive Director for another five years ensures continuity in leadership. The adoption of the new tax regime will impact future tax planning and financial reporting starting from FY27.

Risks to watch

Investors should monitor potential future impacts from the implementation of the new Labour Codes, as management indicated that further clarifications could lead to additional financial adjustments. The recoverability of real estate investments remains a point of caution. The company's ability to sustain revenue growth while managing operational costs and regulatory changes will be crucial.

Peer comparison

Alkem Laboratories operates in a competitive pharmaceutical market. While specific peer comparisons are not detailed in the filing, other major Indian pharmaceutical companies have also been navigating the complexities of regulatory changes, including the implementation of new labour laws and shifts in tax policies. Revenue growth is a key metric for comparison, alongside profitability and dividend policies.

Context metrics (time-bound)

• Revenue Growth: Q4 FY26 revenue increased by 14.7% year-on-year.
• Profit Impact: Q4 FY26 profit declined by 22% year-on-year.
• Dividend: Final dividend of ₹10 per share recommended (₹43 interim already declared).
• Tax Regime: Decision to adopt new tax regime from FY27.

What to track next

Investors should closely watch Alkem Laboratories' future quarterly results to assess the impact of the new tax regime and any further implications of the Labour Codes. Management commentary on growth drivers and margin sustainability will be key. The successful integration and performance of the business post-strategic tax decisions and any further clarity on exceptional items will also be important indicators.